Focus
Pain + Recovery
Category
Repair Support
Format
Research Guide
Method
Labs + Screening
Recovery Support Sheet

Pain Relief
Recovery Protocols

Protocols below are organized by intended outcome and modeled around dosing patterns reported in clinical literature when available. For compounds without established human trial dosing, commonly discussed research-community reference ranges are included for educational comparison only.

!

Research + Safety Notice

This page is provided strictly for research and educational discussion purposes only. Nothing presented here should be interpreted as medical advice, diagnosis, treatment guidance, or a recommendation to use any compound or protocol. The information presented is not a substitute for professional medical care, evaluation, or individualized healthcare guidance.

The compounds, stacks, and protocol structures shown throughout this page are not intended to represent a complete or comprehensive list of options for pain, neuropathy, inflammation, injury recovery, fatigue, or regenerative support. These are simply research-oriented protocols that have been personally explored, observed, discussed, or followed within anecdotal research settings and case-based experiences regarding how they appeared to perform under those specific conditions.

Individual response, risk profile, tolerance, medical history, concurrent medications, and long-term outcomes can vary substantially. What appears beneficial in one research context may not translate similarly elsewhere.

Before considering any peptide protocol, baseline bloodwork is strongly encouraged. Common starting labs may include CBC, CMP, fasting glucose, A1C, lipid markers, inflammatory markers, liver enzymes, kidney function, and hormone panels.

Appropriate cancer screening is also strongly encouraged before beginning regenerative or recovery-focused peptide research. Peptides associated with angiogenesis, tissue repair, growth signaling, or regeneration may carry higher theoretical risk in the presence of active, undiagnosed, or pre-existing malignancy.

Compounds frequently discussed within this caution category include BPC-157, TB-500, GHK-Cu, IGF-related peptides, and other regeneration or growth-signaling compounds. Personal risk factors, family history, pre-existing conditions, laboratory findings, and age-appropriate cancer screening should all be carefully reviewed with a qualified healthcare professional prior to considering experimental use.

01

Clinical Reference Dosing

Compound
Reference Pattern
Primary Outcome Area
ARA-290 / Cibinetide
2–4 mg daily, commonly studied over a 28-day cycle
Neuropathy research, small fiber nerve support, burning and tingling discomfort
BPC-157
200–500 mcg once or twice daily for 4–8 weeks is commonly referenced in research communities
Soft tissue, tendon, ligament, joint, gut, and injury-recovery support
TB-500
2–5 mg weekly divided into 2 doses during a loading phase, then lower maintenance use
Systemic recovery, mobility, tissue repair, and inflammation support
KPV
250–500 mcg daily is commonly discussed in inflammatory-support protocols
Inflammation balance, gut-linked inflammation, and immune-calming support
GHK-Cu
Topical or systemic protocols vary widely; 1–2 mg systemic use is commonly referenced
Skin quality, tissue repair, regenerative signaling, and wound recovery support
Thymosin Alpha-1
1.6 mg subcutaneous, commonly used twice weekly in clinical literature
Immune modulation, inflammatory balance, and recovery support
MOTS-C
5–10 mg weekly or 500 mcg–1 mg daily during active cycles are commonly discussed approaches
Mitochondrial support, recovery capacity, fatigue, and metabolic resilience
+

Best practice: choose the protocol by outcome first, keep the cycle simple enough to track, and avoid stacking too many changes at once.

02

Outcome-Based Protocols

Soft Tissue

Joint + Mobility Support

For tendon, ligament, muscle, joint, or stiffness-focused recovery.

Core: BPC-157
Pairing: TB-500 for broader tissue-repair support
Cycle: 4–8 weeks, then reassess comfort and function
Neuropathy

Nerve Comfort Support

For burning, tingling, sensitivity, small fiber discomfort, or nerve irritation.

Core: ARA-290
Reference: 28-day clinical-style cycle
Pairing: GHK-Cu or NAD+ for repair and cellular support
Inflammation

Calm Recovery Support

For inflammatory discomfort, flare patterns, gut-linked inflammation, or slow recovery.

Core: KPV
Pairing: Thymosin Alpha-1 when immune balance is the priority
Cycle: 4–12 weeks depending on response and tolerance
03

Stack Options

Injury Recovery

BPC-157 + TB-500

A common repair-focused pairing for localized injury patterns, stiffness, restricted movement, or slow soft tissue recovery.

Best fit: tendon, ligament, muscle, joint
Support: protein intake, hydration, gentle movement
Nerve + Repair

ARA-290 + GHK-Cu

A targeted nerve-comfort stack with added tissue-quality and regenerative support.

Best fit: neuropathy-style discomfort
Support: sleep, glucose stability, inflammation control
Fatigue + Healing

MOTS-C + NAD+

A cellular-energy pairing for recovery capacity, fatigue, and stamina during a longer repair phase.

Best fit: low energy, slow rebound, poor stamina
Support: electrolytes, rest days, consistent nutrition
04

Protocol Notes

Track the Baseline

Record pain level, mobility, sleep, inflammation, energy, and daily function before starting.

+ Add Slowly

Introduce one compound or stack at a time so the response is easy to understand.

Evaluate by Weeks

Tissue and nerve recovery are usually assessed over weeks, not single days.

Keep the Foundation

Hydration, protein, electrolytes, sleep, and movement remain part of the protocol.

!

Important Notice

This page exists solely for educational and research discussion purposes. Nothing presented here should be interpreted as medical advice, diagnosis, treatment guidance, or a recommendation to use any compound.

The compounds and stacks listed are not a complete list of options for these types of concerns. They reflect selected research protocols and anecdotal observations from specific research contexts only.

Peptides may carry unknown risks, especially long-term or when combined. Certain regenerative and angiogenesis-associated compounds may theoretically accelerate existing malignancy or abnormal cellular growth.

Professional medical supervision, baseline laboratory testing, and appropriate cancer screening are strongly encouraged before considering any experimental recovery or regenerative protocol.